Metropolis Healthcare Limited plans B2C price rise in Q4 FY27

Metropolis Healthcare Limited plans a calibrated business-to-consumer, or B2C, price rise for part of its operations in Q4 FY27, following a two-year pause and Q2 FY27 revenue growth of 16% year-on-year to Rs 497 crore without a price increase. The proposed revision will vary by micro-market rather than apply uniformly.

Why is Metropolis considering a B2C price rise?

Metropolis is considering the B2C revision because operating inputs, transportation, logistics and service costs have risen over the past two years, management said on the Q2 FY27 call. The company said it expects to pass on only a portion of those increases and believes its volume trends and the shift toward organised diagnostic providers leave room for a calibrated adjustment without a meaningful effect on volumes.

The proposal follows growth that management said was driven by volume and test mix rather than pricing. Patient volumes increased 10% and test volumes rose about 11% year-on-year in Q2 FY27, while revenue increased 16%. Management attributed the balance of revenue growth beyond volumes to a richer test mix and better realisation, rather than a list-price increase.

Metropolis last increased prices in January 2025. Management said the company paused pricing action for one year after a goods and services tax, or GST, law gave it an input benefit, allowing time to ensure tax compliance. Ameera Shah said price increases have historically occurred every one or two years in both organised and unorganised diagnostics, but management did not say whether other providers would raise prices in the current cycle.

How will Metropolis set prices across micro-markets?

Metropolis plans different price changes by micro-market rather than a uniform regional or national increase. Management said its analysis will consider peer benchmarks, market share, competitive intensity and brand equity in each local market. The company had not determined the exact change for any market when it held the Q2 FY27 earnings call.

The intended revision is restricted to B2C at this stage, according to management. It is not yet tied to a particular geographic region, and the company said it needed a couple of months to complete the analytics and groundwork. On a later question, management said it expected the work to take roughly four to six weeks before it could move toward an early-next-year launch.

This local approach matters because Metropolis reported different growth characteristics by area and channel. Tier 3 and rural centres grew revenue by around 20% and represented 26% of domestic revenue in Q2 FY27, while North India accounted for around 17% of domestic revenue. In the West, including Mumbai, Pune and Surat, management cited 16% to 17% growth, but said there was no credible market-share data to quantify its position in Mumbai.

What supported Metropolis growth without price increases?

Metropolis grew B2C revenue 17% year-on-year in both Q2 FY27 and the first half, or H1, of FY27, supported by 13.5% patient-volume growth and 11% test-volume growth. Existing centres delivered same-store growth of 10%, while the company added 116 collection centres during the quarter and reached net additions of 700 centres over the preceding 24 months.

B2B revenue grew 15% in Q2 FY27, with patient volumes up 7% and test volumes up 11%. Management said the difference indicated that partners were sending more tests per patient. The B2B partner network exceeded 9,000 partners, and Metropolis said its partner portal provides test-menu, pricing, account-statement and daily-performance visibility to these partners.

The Specialty and TruHealth segments each grew around 20% year-on-year. Specialty contributed 40% of Q2 FY27 revenue, while TruHealth contributed 17%. Metropolis added 43 specialty and super-specialty tests in H1 FY27, and management said cross-selling Core Diagnostics' oncology portfolio supported Specialty demand. It also said genomics remains relatively early in development, following roughly 1.5 to two years of activity.

Metropolis said the growth did not rely materially on revised Central Government Health Scheme, or CGHS, rates because CGHS contributes minimally to revenue. Its TruHealth test metric also counts each wellness package as one test, even if a package contains 50 or 60 parameters. Management cited that convention in explaining why the reported tests-per-patient figure can appear lower than some industry comparisons.

What could the Q4 FY27 price rise mean for margins?

A B2C price rise could add to Metropolis' margin improvement, but management also disclosed planned investments that may offset part of the benefit. Q2 FY27 earnings before interest, tax, depreciation and amortisation, or EBITDA, margin was 27.2%, up 180 basis points year-on-year. EBITDA rose 24% to Rs 135 crore, while profit after tax, or PAT, rose 43% to Rs 75 crore and PAT margin increased 290 basis points to 15.2%.

Management attributed the Q2 margin expansion to volume-led operating leverage, cost discipline and productivity measures. Its workforce has remained broadly stable for several quarters while test volume grew about 10% to 11% year-on-year. The laboratory-platform transition, covering a common test menu, equipment, reagents, turnaround times and vendor consolidation, was scheduled for completion in Q3 FY27 and is intended to support gross margins thereafter.

The company is also increasing network density by taking the collection-centre-to-lab ratio from 24:1 toward 30:1 and then 35:1 over the next two years. It said it had stopped adding more labs and was operating in 750 towns, instead adding collection centres in existing markets. Management expects to add about 25 mini hubs and allied retail products in parallel, which it said will require investment.

For FY27, management said H1 revenue growth of about 16% and EBITDA-margin expansion of 180 to 200 basis points could continue through the rest of the year. In the coming years, management sees an opportunity for a further 125 to 150 basis points of margin improvement, net of investment in mini hubs and other initiatives. That outlook is management’s assessment, not a declared financial target tied solely to the proposed price rise.

Conclusion

Metropolis' planned Q4 FY27 B2C pricing action is a selective cost-recovery lever, not the stated basis for its Q2 FY27 performance. Revenue rose 16% to Rs 497 crore before any new price increase, with B2C up 17%, B2B up 15%, and Specialty and TruHealth each growing around 20%. The micro-market design means that local competition, positioning and brand equity will determine implementation rather than a single company-wide rate.

The next milestone is completion of the price-analysis work over the next several weeks and a potential Q4 FY27 rollout for part of the B2C business. Management is also scheduled to provide an update after Q3 in early Q4, when investors can assess whether the laboratory-platform transition is complete, whether centre additions lift the 24:1 centre-to-lab ratio, and how planned mini-hub investment affects margins.